Compare Abeona Therapeutics Inc (ABEO) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.17. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| ABEO | SLVO | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $107.41 |
52-Week Low | $4.17 | $62.46 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SLVO trades at $68.09, up 1.99% with bearish technical signals from moving averages and mixed oscillators. The stock shows strong momentum indicators with RSI extremes suggesting potential reversal zones. Support and resistance levels cluster tightly around $67-69, indicating critical price decision points ahead.
The technical setup suggests near-term consolidation with bearish momentum prevailing. Investment opportunity exists for contrarian plays at support levels, though risks include the strong bearish technical bias and potential for breakdown below key support. Market sentiment appears cautious pending fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
